Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 22.23 0.3 (1.37%) Market Cap: 2.02 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 4.56 GF Score: 39/100

Rocket Pharmaceuticals Inc Danon Update Call Transcript

Nov 15, 2021 / 01:30PM GMT
Release Date Price: $25.9 (-23.67%)
Operator

Welcome to the Rocket Pharmaceuticals Inc. Danon Update Webcast Conference Call. My name is John. I'll be operator for today's call.

(Operator Instructions) Please note, the conference is being recorded. And I will now turn the call over to Mayur Kasetty.

Mayur Kasetty

Good morning. This is Mayur Kasetty, Director of Business Development and Operations and Investor Relations lead at Rocket Pharmaceuticals. Thank you for joining us.

The purpose of this call is to share and discuss key updates on our ongoing Phase I clinical trial of RP-A501 in Danon disease, which includes data that is being presented in an e-poster at the ongoing American Heart Association 2021 Scientific Sessions.

Before we begin, I would like to briefly discuss the use of forward-looking statements on this conference call. Statements we make on this call may include statements which are not historical facts and are considered forward-looking within the meaning of the securities laws and which are usually identified by the use of words such as anticipates, believes,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot